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INTRODUCTION
Protein synthesis is an essential process in all cells. The ribosome performs this task by translating the genetic information encoded in messenger RNAs (mRNAs) into proteins (1, 2). The bacterial ribosome is composed of three RNA chains (16S, 23S, and 5S) and more than fifty proteins assembled into two individual subunits, the small 30S and the large 50S subunits, which join together to form the 70S ribosome (3) . For translation to proceed efficiently, many protein factors are needed and interact sequentially with the ribosome. Through highly regulated and choreographed steps, translation factors guide the ribosome during the protein synthesis cycle, which can be divided into four main steps: initiation, elongation, termination, and ribosome recycling (3).
Protein synthesis is initiated on the 30S subunit with the help of initiation factors which recruit the initiator formyl-methionine transfer RNA (fMet-tRNAi fMet ) in the ribosomal peptidyl (P) site
[reviewed in (4) ]. The 50S subunit associates with the 30S, forming the 70S initiation complex (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) . Subsequently, multiple crystal structures of the 70S ribosome were obtained (28) (29) (30) , which opened further possibilities for understanding the mechanism of protein synthesis and the action of ribosome-targeting inhibitors.
This review seeks to provide a one-stop resource for those interested in the mechanisms of action and resistance of ribosome-targeting inhibitors. Because antibiotics inhibit protein synthesis by targeting specific functional centers of the ribosome, we discuss inhibitors based on their binding sites in the ribosome. We describe their modes of action, as well as prominent examples of the resistance mechanisms that have developed among pathogens. Finally, we discuss approaches currently being used to identify new antibiotics.
ANTIBIOTICS TARGETING THE SMALL SUBUNIT OF THE RIBOSOME

Antibiotics that bind in the decoding center.
The decoding center (DC) is the region comprising the A site on the 30S subunit that monitors the correct base pairing between the mRNA codon and the anticodon of the aa-tRNA. This part of the ribosome consists of regions of the 30S head, shoulder and the top of helix 44 (h44) of 16S rRNA.
Biochemical (31) (32) (33) and structural studies (25, 34) have shown that conserved nucleotides A1492, A1493 (h44), and G530 (h18) play a critical role in the decoding process. Binding of cognate tRNA in the A site makes nucleotides A1492 and A1493 flip out of h44 and form A-minor interactions that monitor the geometry of the first two codon-anticodon base pairs, ensuring that only Watson-Crick pairs are accepted (34) . The base pair geometry in the third position of the codon is monitored less strictly by ribosomal protein uS12 (Pro45) and nucleotide G530, allowing wobble base pairs in this position (Figure 1c ) (34) . translocation and stimulating miscoding (36) .
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The region of the 30S subunit consisting of h44 and its immediate vicinity is targeted by several classes of antibiotics. Streptomycin interacts with h44, h27, h18 and ribosomal protein uS12, inducing conformational changes of nucleotides A1492 and A1493 (Figure 2c ) (25, 37) .
Aminoglycosides, such as paromomycin and gentamicin, bind at the top of h44 and induce conformational rearrangements of A1492 and A1493 similar to those induced by streptomycin (Figure 2d ,e) (25) . These drugs favor the flipped-out conformation of A1492 and A1493, and thereby increase miscoding by stimulating the binding of near-and non-cognate tRNAs in the A site. Hygromycin B, another aminoglycoside antibiotic, which, however, does not stimulate miscoding, increases the affinity of tRNA for the A site, and similarly to negamycin, inhibits tRNA translocation (Figure 2f Thermorubin is chemically related to tetracyclines. However, it binds to the ribosome in a completely different site, namely at the interface between the small and the large subunits where h44 and H69 form the inter-subunit bridge B2a. Thermorubin induces rearrangement of two bases in H69 of the 23S rRNA (44), leaving the displaced nucleotide C1914 in H69 in a position where it would collide with an A-site tRNA (Figure 2i ), which explains its inhibitory effect on the initiation and elongation steps of protein synthesis.
2.2
Antibiotics that bind to the P and E sites in the 30S subunit.
The P and exit (E) sites in the 30S subunit refer to the locations occupied by the anticodon loops of the peptidyl-and deacyl-tRNAs, respectively, during translation. The E site is the third and final binding site for a tRNA before it dissociates from the ribosome. Antibiotics that bind to the P and E sites in the 30S subunit are generally referred to as translation initiation inhibitors, but some of Annual Review of Biochemistry P a g e | 6 of 36 them also affect tRNA and mRNA translocation. These antibiotics include kasugamycin, pactamycin, edeine, GE81112, and amicoumacin A. The binding site of kasugamycin spans both the P and E sites in a position that overlaps with the mRNA (Figure 3a) (45, 46). The position of the bound drug is incompatible with the canonical location of mRNA, preventing formation of the 30S initiation complex. Similarly, pactamycin also disturbs the path of the mRNA and prevents the formation of the 30S initiation complex by binding to the E site of the small subunit ( Figure   3b ) (26, 47) . Amicoumacin A is another potent protein synthesis inhibitor that binds to the E site of the small subunit. The crystal structure of the 70S ribosome carrying mRNA and tRNAs and with amicoumacin A bound revealed that this antibiotic simultaneously interacts with conserved nucleotides of the 16S rRNA in the E site and with the mRNA phosphate backbone, thereby tethering mRNA to the ribosome and preventing its translocation (Figure 3c ) (47).
The cationic peptide antibiotic edeine binds to the P site of the small subunit and induces base pair formation between C795 and G693 in the 16S rRNA (24) , thereby preventing the binding of fMettRNAi fMet to the small subunit (Figure 3d) . Conversely, the tetrapeptide antibiotic GE81112, which also binds to the P site of the small subunit, prevents proper P site decoding by stabilizing the anticodon-stem loop of fMet-tRNAi fMet in a distorted conformation (Figure 3e ) (48). This results in a stalling of the initiation step of protein synthesis caused by a reduction in the association rate for the 50S subunit (48).
While ribosome protein uS13 contributes significantly to the binding of GE81112 (Figure 3e ), ribosomal protein uS12 in the 30S subunit is also an important component of the ribosome. In an effort to overcome the shortage of new antibiotics, natural compound library screens are now being performed to detect bioactive molecules that could be further improved by rational drug design, fragment-based drug discovery and computational chemistry. Such screens have led to the identification of GE82832, a peptide antibiotic produced by Streptosporangium cinnabarinum (strain GE82832) that inhibits tRNA translocation by interacting with the 30S subunit (49). Further analysis revealed that GE82832 is related to a poorly characterized antibiotic called dityromycin that was discovered decades ago (50). Characterization of both antibiotics has shown that they are structurally and functionally related, and inhibit EF-G-dependent tRNA translocation on the ribosome (51). The crystal structure of the 70S ribosome in complex with dityromycin and GE82832 showed that both antibiotics bind exclusively to ribosomal protein uS12 (52). To our knowledge, dityromycin and GE82832 are the only two ribosome-targeting antibiotics that bind
Annual Review of Biochemistry solely to a ribosomal protein in the bacterial ribosome. The mechanism by which dityromycin and GE82832 interfere with tRNA and mRNA translocation has recently been elucidated using a crystal structure of EF-G bound to a dityromycin-70S ribosome complex (Figure 3f ) (53). The binding of dityromycin to protein uS12 traps EF-G in a compact conformation on the ribosome, inhibiting EF-G-mediated tRNA translocation.
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ANTIBIOTICS TARGETING THE LARGE SUBUNIT OF THE RIBOSOME
Antibiotics that bind the peptidyl transferase center.
The majority of antibiotics that bind to the 50S subunit cluster at the PTC, where the peptide bond formation occurs, and within the nascent peptide exit tunnel (NPET) (Figure 1d) . Because all aa-tRNAs make key interactions with the ribosome in the A site, chloramphenicol was viewed as a universal inhibitor of peptide bond formation. However, this commonly accepted model of chloramphenicol action fails to explain several experimental observations such as the differential inhibition of translation of specific mRNA templates (55) . There is increasing evidence that chloramphenicol acts in a context-specific way and that its activity critically depends on the nature of specific amino acids in the nascent chain and the identity of the residue entering the A site (55).
The binding of chloramphenicol to the A-site crevice strikingly resembles that of another drug, anisomycin, which is effective only against archaeal and eukaryotic, but not eubacterial ribosomes.
The specificity of chloramphenicol for the bacterial ribosome versus that of anisomycin for the archaeal Haloarcula marismortui 50S (16) can be explained by a steric collision that would occur between anisomysin and U2504 (that pairs with C2452) in the bacterial ribosome. The reorientation of U2504 and G2505 observed in the H. marismortui 50S subunit widens the A-site cleft (14) , providing a rationale for the specificity of anisomycin for the archaeal ribosome.
The antibiotic linezolid, a member of the oxazolidinone family, is active against all major (Figure 4c ) (61) . Similarly, the sulfur-containing tail of sparsomycin forms hydrophobic interactions with the A-site crevice (22, 60, 62) , illustrating the similarity of the strategies used by small molecules to target the PTC region of the ribosome. The remaining moieties of sparsomycin, the pseudouridine group and a part of its tail, are sandwiched between the CCA-end of the P-site tRNA and the base of A2602 (Figure 4d ) (22, 60, 62) . In this position, sparsomycin stabilizes the binding of the P-site tRNA, which explains why it induces translocation of an A-site tRNA to the P site (63) .
Antibiotic A201A, which is structurally similar to puromycin, is active against Gram-positive bacteria and most Gram-negative anaerobic species (64) . Hygromycin A shares its dihydroxyphenyl and hexofuranose rings with A201A and has broad-spectrum activity against
Gram-positive and, to a lesser extent, Gram-negative bacteria (65, 66) . The structures of hygromycin A and A201A bound to the ribosome show that their dihydroxyphenyl moieties localize in the A-site crevice, and stack on the base of C2452 (67) . These structures and single- (22) and inhibits binding of Aand P-site substrates (69, 70) . In this case, the oxazole ring of virginiamycin M reaches into the Asite cleft, where it establishes hydrophobic interactions (22) .
Pleuromutilins, such as lefamulin, are a class of antibiotics that are active against drug-resistant pathogens. They inhibit protein synthesis by binding to the PTC and interfering with the coordination of both A-and P-site tRNAs. In the crystal structure of the S. aureus 50S subunit (10), the tricyclic mutilin core moiety of lefamulin forms hydrophobic stacking interactions with nucleotides U2504 and C2452, anchoring the drug to the ribosome and blocking the A site ( Figure   4g ). The C14 extension on the tricyclic core of lefamulin points into the P site, thereby hindering tRNA positioning at the P and A sites.
Blasticidin S, produced by some species of Streptomyces, is a nucleoside analog consisting of a cytosine linked to a pyranose sugar ring and attached to an N-methyl-guanidine tail. It is a potent inhibitor of protein synthesis in bacterial and eukaryotic cells (71, 72) . The crystal structure of the H. marismortui 50S subunit bound to blasticidin S revealed that it occupies the P site of the large subunit where it would presumably compete with the binding of the P-site tRNA (22) . However, observations that blasticidin S enhances binding of aa-tRNA-mimics to the P site (73) and decreases binding of the same tRNA mimics to the A site (73, 74) , combined with the fact that blasticidin S competes for binding with sparsomycin (75) and puromycin (76) , two antibiotics that bind the hydrophobic A-site cleft, raised doubts that the 50S crystal structure fully explained its mode of action. The crystal structure of blasticidin S in complex with the Thermus thermophilus 70S ribosome with tRNAs shows that antibiotic molecule forms a Watson-Crick-like interaction with nucleotide G2251 in the P-loop of the 23S rRNA and distorts the 3'-termini of the P-site
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tRNA by intercalating between nucleotides C74 and A76 of the P-site tRNA, thereby displacing C75 from its normal position in the PTC (Figure 4h ) (77) . Biochemical experiments show that distortion of the P-site tRNA by blasticidin S inhibits peptidyl-tRNA hydrolysis promoted by release factors, rather than peptide bond formation (77) . Furthermore, blasticidin S and chloramphenicol were recently reported to inhibit subunit dissociation mediated by EF-G and RRF, or low magnesium concentrations (78) . This highlights the often promiscuous and collateral effects of antibiotics binding to functional centers that are critical for various ribosomal activities.
The polyketide-peptide family of molecules produced by Burkholderia thailandensis, like bactobolin A, inhibit protein synthesis (79) . Mutations in ribosomal protein uL2 that would disrupt the E236:A2450 contact in the PTC leads to bactobolin A resistance (80, 81) , but the ribosome remains susceptible to other known antibiotics, which hinted that bactobolin A binds to a new location on the ribosome. However, the reported structure of the bacterial ribosome bound to bactobolin A (81) shows that its binding site overlaps with that of blasticidin S, and that it distorts the CCA-end of the P-site tRNA toward the A site, suggesting that both antibiotics may interfere with protein synthesis the same way (Figure 4i ).
Antibiotics that bind in the NPET.
The nascent polypeptide chain remains attached to a tRNA molecule inside the ribosome at all times during translation until it is hydrolyzed by a release factor and released from the ribosome in response to a stop codon. During this process, a part of the synthesized polypeptide chain is located in the NPET -an important structural and functional element of the ribosome (5, 8, 54 ).
The function of the exit tunnel appears to be not only to provide an unobstructed passage through the ribosome for newly synthesized polypeptide chains but also to regulate translation itself.
Specific elements of the tunnel monitor the amino acid sequence of the nascent polypeptide chain, and arrest of translation may occur in response to particular drugs or metabolites (82, 83) . The NPET is the target for many clinically important antibiotics (23, 27, 54, 59 ) and its alteration can lead to antibiotic resistance in pathogenic bacteria (84) (85) (86) (87) . and partially blocking it, macrolides were initially thought to simply obstruct the progression of the nascent polypeptide chain resulting in peptidyl-tRNA drop off and abortion of protein synthesis. As in the case with chloramphenicol and linezolid, that model for the mechanism of macrolide action has had to be amended as new data have become available. Currently, there is compelling evidence that macrolides inhibit translation in a context-specific manner by interfering with polymerization of only certain amino acid sequences (88, 89) . Some proteins lack the "problematic" sequences and continue to be synthesized when macrolide antibiotics are bound in the exit tunnel (90) .
The most recent structures of erythromycin in complex with the 70S ribosome from T.
thermophilus (91) and E. coli (59) reveal that the desosamine sugar, an essential element of every macrolide, interacts with A2058 and A2059 of the 23S rRNA. This is consistent with probing experiments showing that macrolides protect A2058 and A2059 from chemical modification (92) .
Methylation of A2058 or its mutation to G renders ribosomes macrolide-resistant (Figure 8c ) (93) .
Curiously, archaeal and eukaryotic ribosomes have a G in the position equivalent to A2058, making them naturally resistant to macrolides. Although the mutation G2058A in archaea enhances erythromycin binding (18) , the same mutation in yeast is not sufficient to render ribosomes susceptible to erythromycin, suggesting that other determinants contribute to resistance in eukaryotes (94) .
Larger macrolides, such as 16-membered tylosin, carbomycin A, and spiramycin have a disaccharide extension at the C5 position of their macrolactone ring. This extended tail can reach deeper into the PTC and interfere with the peptide bond formation when these drugs are bound to the ribosome (23) . Erythromycin lacks such a tail. These drugs directly inhibit peptide bond formation to varying extents (carbomycin A -100%, spiramycin -85%, and tylosin -60%) (95) .
The strong inhibition of peptide bond formation by carbomycin A is likely due to the presence of the isobutyrate extension on the C5-disaccharide that collides with the amino acid of aa-tRNAs (Figure 5b ) (23) .
Ketolides are semi-synthetic derivatives of macrolides in which the sugar in position C3 is replaced with a keto group. Telithromycin is a ketolide that is derived from 14-membered macrolides, and it is representative of a new generation of antimicrobials that has been developed to overcome the problem of macrolide resistance; it is active against erythromycin-resistant pneumococci (96) . P a g e | 13 of 36
Telithromycin has an alkyl-aryl arm that extends from positions C11/C12 and forms a stacking interaction with base-pair A752-U2609 of the 23S rRNA (Figure 5c ). This additional point of contact increases the affinity of telithromycin for the wild-type ribosome by 10-fold compared to erythromycin (97) . However, adverse side effects have limited the clinical use of telithromycin (98) and led to its withdrawal from the market. For that reason, new ketolides are being sought that will fight bacterial infections while having fewer side effects. The fluorine-containing ketolide solithromycin (CEM-101) is a promising drug of this class (99) . The structure of solithromycin bound to the E. coli ribosome (100) shows that its binding site is similar to that of telithromycin (59, 91) , with differences being confined to the interactions mediated by the alkyl-aryl extension, which appears to anchor solithromycin to the ribosome better than telithromycin (100).
The exit tunnel of the ribosome is also targeted by type B streptogramins (SB), such as pristinamycin IA, quinupristin, and virginiamycin S. While type A streptogramins (SA) contain a 23-membered unsaturated ring with lactone and peptide bonds, SB antibiotics are depsipeptides produced by various species of Streptomyces. Crystal structures of SA (22, 68, 101) and SB (20, 101) antibiotics in complex with the ribosome show that both classes bind to adjacent, but not overlapping, sites on the ribosome, which explains their synergistic action (Figure 5d ) (102) . As discussed above, SA antibiotics bind at the PTC and prevent proper positioning of the A-and Psite tRNAs, whereas SB antibiotics bind to a site that overlaps with that of macrolides and presumably interfere with the passage of the nascent peptide through the exit tunnel. Interestingly, nucleotide A2062 of the 23S rRNA is sandwiched between quinupristin and the macrocyclic ring of dalfopristin (20, 101) , rationalizing why mutation A2062C in the 23S rRNA of Streptococcus pneumoniae leads to SA and SB cross-resistance (103) . Several streptogramins that are approved for clinical use, such as Synercid, a mixture of type A streptogramin dalfopristin and type B streptogramin quinupristin (Figure 5d ) (101) , are effective against methicillin-resistant Staphylococcus aureus (MRSA) (104).
Ribosome inhibition by antimicrobial peptides.
The cecropins, which were discovered more than 35 years ago, is a group of antibacterial peptides (AMPs) produced by insects to protect them from pathogen infections (105) . They are now known to be widely expressed in both animals and plants. Because of their potential as therapeutic agents, we will discuss one sub-class of AMPs, the proline-rich antimicrobial peptides (PrAMPs), which are expressed in both mammals and insects. They have attracted attention because of their wide distribution, and because they kill bacteria by mechanisms that do not involve cell-membrane disruption (106) . Oncocin, apidaecin, drosocin, pyrrhocoricin, metalnikowin and bactenecin 7 are
PrAMPs known to interact with micromolar affinity with the substrate-binding domain of the chaperone DnaK, leading to protein misfolding and aggregation, and ultimately bacterial death (107, 108) . However, DnaK-deficient E. coli strains remain susceptible to PrAMPs, indicating that
PrAMPs have other targets inside the cell (109).
The mystery of the primary cellular target of these insect-derived PrAMPs remained unsolved until it was discovered that oncocin and apidaecin bind to the 70S ribosome with nanomolar affinities (109) . These results explain why DnaK null mutant E. coli strains remain susceptible to apidaecin and oncocin. Similarly, it was reported that bactenecin 7, which belongs to the cathelicidin family, (Figure 5f ). Contrary to other PrAMPs, for which structures are available, the orientation of Api137 matches that of a nascent polypeptide chain.
Although several inhibitors, such as blasticidin S, bactobolin A, and negamycin, have been reported to interfere with translation termination (77, 81, 118) , these antibiotics also hamper other steps of protein synthesis. This makes apidaecin the first inhibitor known to be specific for the termination step of translation. The mode of interaction of these PrAMPs with the exit tunnel of
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A ribosomally-synthesized post-translationally modified peptide (RiPP), klebsazolicin (KLB) that directly inhibits the ribosome was recently identified using a genome mining approach (119) .
Structural analysis of the ribosome-KLB complex reveals that the compound binds in the peptide exit tunnel to a site that overlaps with the binding sites of macrolides, SB, the PrAMPs Onc112 and Bac7, and significantly obstructs the tunnel (Figure 5g ) (119) . Unlike PrAMPs, which are highly enriched in positively charged amino acids and interact with the negatively charged rRNA backbone, KLB interacts with the ribosome mainly via stacking of heterocycles over rRNA bases.
Unlike the PrAMPs, which bind the ribosome in an elongated conformation, KLB binds the exit tunnel in a compact, globular conformation.
Antibiotics that interfere with translation factors.
Thiopeptide A new antibiotic binding site on the ribosome has recently been discovered from the structures of the 70S ribosome in complex with the orthosomycin antibiotics evernimicin and avilamycin (9, 121) . Both antibiotics adopt elongated conformations spanning the minor grooves of helices H89
and H91 of the 23S rRNA, contacting few arginine residues of ribosomal protein uL16 (Figure   6b ). In this location, evernimicin has been reported to inhibit formation of the IF2-dependent 70S initiation complex and to prevent accommodation of the aa-tRNA into the A site on the large subunit (122, 123) .
MECHANISMS OF ANTIBIOTIC RESISTANCE
General mechanisms of antibiotic resistance.
The development of resistance to antibiotics often rapidly follows their introduction into the clinic.
Antibiotics that target the ribosome are no exception. Antibiotic resistance, however, should be considered as an ancient feature, since naturally produced antibiotics have existed in the environment for billions of years and resistance to them was spread among environmental and pathogenic bacteria way before modern use of antibiotics to cure infections (124) . Resistance to antibiotics is inherently linked to their production because microorganisms that produce antibiotics must be able to protect themselves against the action of the drugs they make. These intrinsic aminoglycosides into the cell is driven by energy produced by oxidative metabolism, which these bacteria cannot perform. In addition, bacteria can develop resistance by increasing the efflux of a particular drug, thereby lowering its concentration inside the cell to a non-toxic level. This can be achieved by acquisition of genes encoding drug-specific efflux pumps or chromosomal mutations resulting in overexpression of a pre-existing efflux pump, such as for example the multidrug efflux pump TolC in E. coli (125) . The drug resistance that is conferred by the up-regulation of the efflux pumps is known for almost all ribosome-targeting antibiotics. For some antibiotics, enhanced antibiotics more frequently arises from mutations of ribosomal proteins, whose genes usually exist as a single copy in the genome. Besides mutations, antibiotic binding sites can also be altered by enzymatic modification, which affects all copies of rRNA in the cell and leads to strong resistance.
In one known case, resistance to kasugamycin that arises from the loss of an intrinsic modification in the 16S rRNA caused by inactivation of the responsible enzyme (127) .
Although the mechanisms of resistance are very diverse for any given antibiotic, one mechanism often prevails for many pathogens. Next, we highlight the major mechanisms of resistance that emerged from the clinical use of some important ribosome-targeting antibiotics.
Mechanisms of resistance to tetracyclines.
Tetracycline resistance usually results from the acquisition of mobile genetic elements carrying tetracycline-specific resistance genes that encode for efflux pumps, ribosome protection proteins (RPPs), and drug-degrading enzymes (Figure 7) . Tetracycline-specific efflux pumps are most effective against 1 st generation tetracyclines. They confer moderate resistance to the 2 nd generation tetracyclines, such as doxycycline and minocycline, and little resistance to the 3 rd generation tetracyclines (also called glycylcyclines), such as tigecycline (128) . Use of RPPs is another way to resist the inhibitory action of tetracyclines. RPPs, represented by TetO and TetM, are paralogues of EF-G (129). They bind to the tetracycline-stalled ribosome and cause dissociation of P a g e | 18 of 36 tetracycline from the ribosome (Figure 7) . A cryo-EM reconstruction of TetM bound to the E. coli Enzymatic degradation is a mechanism of tetracycline resistance that is rare in the clinic. A flavindependent monooxygenase encoded by the TetX gene modifies tetracycline at position C11a to generate 11a-hydroxyl-tetracycline, which undergoes spontaneous non-enzymatic breakdown (Figure 7) . For a long time, TetX remained the only tetracycline-degrading enzyme that had been characterized biochemically, and that had been detected in few human pathogens (132) . However, a family of widespread TetX-related genes, termed destructases, was discovered recently (133) .
Products of these genes utilize various mechanisms to inactivate tetracycline, but not tigecycline (134) . The existence of the destructase family is alarmingly worrisome. If disseminated into human pathogens and mutated, these genes would exacerbate the problems caused by tetracycline resistance, and, potentially, threaten the clinical application of tigecycline (135).
Mechanisms of resistance to aminoglycosides.
Drug modification by cellular enzymes is the prevalent mechanism of resistance to aminoglycosides. Owing to the exposed amide and hydroxyl groups, aminoglycosides are prone to enzymatic modification. Over 300 enzymes, which can be categorized into three classes, including acetyltransferases (AAC), nucleotidyltransferases (ANT), or phosphotransferases (APH), modify aminoglycosides at their amino groups or hydroxyl groups (Figure 8a ) and cause them to lose ribosome-binding activity (Figure 8b ) (136) . These enzymes, which likely evolved from aminoglycoside-producing bacteria, now exist in transmissible elements posing a significant clinical threat as they confer resistance to a broad range of aminoglycosides.
Resistance to aminoglycosides can also be conferred by ribosomal mutations in pathogens that have one or two copies of rRNA operon. For example, the A1408G mutation in h44 of the 16S rRNA has been found in clinical isolates of resistant M. tuberculosis (137) . Notably, G1408
normally exist in human cytosolic ribosomes, explaining why aminoglycosides are inactive against
Annual Review of Biochemistry P a g e | 19 of 36 human ribosomes and rationalizing their specificity for bacteria. Unlike most aminoglycosides that bind h44, streptomycin interacts with the G530-loop (h18) as well as ribosomal protein uS12 (Figure 2c) . Accordingly, the most frequently occurring mechanism of resistance to streptomycin in M. tuberculosis is a mutation of one of the two lysine residues K43 or K88, both of which contact streptomycin bound to the ribosome (138).
In some clinical isolates, methylation of either G1405 or A1408 mediated by specific 16S rRNA methyltransferases confers resistance to many h44-binding aminoglycosides (139) . The methylase-encoding genes are usually found on plasmids that probably originated in aminoglycosides-producing actinomycetes. It has also been shown that the loss of the normal G527 methylation caused by mutations in a gene encoding a 7-methylguanosine (m 7 G) methyltransferase (RsmG/GidB) confers low-level streptomycin resistance (140).
Mechanisms of resistance to MLSBK antibiotics.
Antibiotics, such as macrolides, lincosamides, streptogramins B, and ketolides (collectively for example, has been shown to contain a wealth of antibiotic biosynthesis genes, and recently two new promising antibiotics, lactocillin and lugdunin, were isolated from human commensals (148, 149) . Ribosomally-synthesized post-translationally modified peptides (RiPPs) are among the most abundant antimicrobial agents synthesized by human microbiota (148, 150) . Recently, the first member of a new class of protein synthesis inhibitors, klebsazolicin (KLB), which comes from the opportunistic human pathogen Klebsiella pneumonia, was discovered using this genome-guided approach (119) . KLB is the first linear azole-containing peptide for which the mode of binding to its target has been structurally characterized (see section 3.3). KLB is synthesized on the ribosome as a precursor, which next undergoes post-translational modifications by dedicated enzymes encoded in a compact gene cluster (119) . Moreover, KLB can be expressed in a surrogate E. coli host, which suggests avenues for future rational drug design: by changing the primary sequence of amino acids in the KLB precursor, we can change properties of the final processed compound.
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CONCLUSION
The rise of pathogens that are resistant to antibiotics warrants the search for new drugs capable of inhibiting bacterial growth and curing infections. Many of the antibiotics currently in use target the bacterial ribosome and usually hamper protein synthesis by binding to ribosomal functional centers, such as the decoding center, the peptidyl transferase center, and the peptide exit tunnel.
High-resolution structures of the ribosome in complex with factors and inhibitors have already been instrumental in advancing our understanding of the mechanism of protein synthesis and its modes of inhibition. As new ribosome functional complex structures become available, we expect that the incremental but crucially important progress on drug discovery will continue and lead to novel protein synthesis inhibitors that will be part of the next-generation antibiotic arsenal.
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Lin et al. 4. High-resolution ribosome structures (3Å or better) can provide reliable structural information for rational drug design. Better availability of the structure acquisition techniques to academic and industrial users can significantly accelerate the entire drug development and optimization pipelines.
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